Industry group warns Ottawa that excessive cuts to drug prices could be harmful | Times Colonist

OTTAWA — Canada’s drug developers recognize that pharmaceutical prices need to come down but they fear the Trudeau government will push too hard in a regulatory review by Health Canada, the head of an industry association said Tuesday.

Pamela Fralick, president of Innovative Medicines Canada, said she doesn’t know what changes Health Canada will propose for the Patented Medicine Prices Review Board under a review launched last spring.

Fralick said the Innovative Medicines group — whose members account for a majority of Canada’s drug research spending — understands that prices need to be lowered.

“But we also want (Canada) to continue to be a strong player in the innovative world, in the broader pharmaceutical world,” Fralick said.

During a question period following her speech, Fralick said a big change in pricing “will mean job loss. It will mean less resourcing for research. It will mean less support for patient programs. . . . How much, I can’t say.”

Read complete article here:

Industry group warns Ottawa that excessive cuts to drug prices could be harmful.